18F-FDG PET/CT-based recurrence patterns and survival outcomes in esophageal carcinoma: a single center experience
References
- Jiang W, Zhang B, Xu J, Xue L, Wang L. Current status and perspectives of esophageal cancer: a comprehensive review. Cancer Commun 2025; 45: 281-331. doi: 10.1002/cac2.12645
- Lander S, Lander E, Gibson MK. Esophageal cancer: overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep 2023; 25: 275-9, doi: 10.1007/s11894-023-00899-0
- Sung J, Lin D, Fitzgerald R, Sharma P, Law S, Ilson D. Carcinoma of esophagus. J Gastroenterol Hepatol 2025; 40: 1861-75. doi:10.1111/jgh.16990
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers [Internet]. [cited 2026 Mar 5]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433
- National Cancer Institute. Esophageal Cancer Treatment (PDQ®)–Patient Version [Internet]. Bethesda (MD): National Cancer Institute; [cited 2026 Mar 15]. Available at: https://www.cancer.gov/types/esophageal/patient/esophageal-treatment-pdq.
- Samoylova ML, Rajaram R. The evolving role of systemic therapy in locoregionally advanced esophageal cancer: a narrative review. Ann Esophagus 2025; 8: 20. doi: 10.21037/aoe-25-11
- Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23. doi: 10.1002/cncr.11228
- Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol 2019; 14: 27. doi: 10.1186/s13014-019-1232-1
- Karahan Şen NP, Aksu A, Çapa Kaya G. Volumetric evaluation of staging 18F-FDG PET/CT images in patients with esophageal cancer. Mol Imaging Radionucl Ther 2022; 31: 216-22. doi: 10.4274/mirt.galenos.2022.38980
- Goense L, van Rossum PS, Reitsma JB, Lam MG, Meijer GJ, van Vulpen M. Diagnostic performance of 18F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. J Nucl Med 2015; 56: 995-1002. doi: 10.2967/jnumed.115.155580
- Clark GW, Ireland AP, Hagen JA, Collard JM, Peters JH, De Meester TR. Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am J Surg 1995; 170: 597-601. doi: 10.1016/s0002-9610(99)80023-3
- Mao YS, Zhang DC, Zhao XH, Wang LJ, Qi J, Li XX. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer]. [Chinese]. Zhonghua Zhong Liu Za Zhi 2003; 25: 457-60. doi: 10.3760/cma.j.issn.0253-3766.2003.05.112
- Das S, Kakoti LM, Ahmed S, Sarma A, Kataki AC. Study of serum CEA and CA 19-9 in esophageal squamous carcinoma and ROC curve analysis. Asian Pac J Cancer Biol 2020; 5: 141-5. doi: 10.31557/APJCB.2020.5.4.141
- Ansari F, Rai A, Shukla S. Study of carcinoma embryonic antigen and carbohydrate antigen 19-9 levels in patients of esophageal cancer. Int Surg J 2021; 8: 3274-8. doi: 10.18203/2349-2902.isj20214060
- Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N, et al. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: a systematic review and meta-analysis. Eur J Cancer 2018; 103: 214-26. doi: 10.1016/j.ejca.2018.07.132
- Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kaspe S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-57, doi: 10.1016/S0140-6736(18)32557-1
- Mantziari S, Pomoni A, Prior JO, Winiker M, Allemann P, Demartines N, et al. 18F-FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imaging 2020; 20: 7. doi: 10.1186/s12880-019-0401-x
- Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31: 496-505. doi: 10.1053/j.sult.2010.10.001
- Kommi S, Rallapeta RP, Subramanian BV, Yadagiri LA, Hulikal N, Chandramaliteeswaran C, et al. Utility of [18F]FDG-PET/CT in initial staging and management of patients with esophageal carcinoma: a tertiary care center experience. Indian J Nucl Med 2024; 39: 329-34. doi: 10.4103/ijnm.ijnm_118_23
- Al-Taan OS, Eltweri A, Sharpe D, Rodgers PM, Ubhi SS, Bowrey DJ. Prognostic value of baseline FDG uptake on PET-CT in esophageal carcinoma. World J Gastrointest Oncol 2014; 6: 139-44. doi: 10.4251/wjgo.v6.i5.139
- Korkmaz U, Hacioglu MB, Kostek O, Sut N, Kodaz H, Erdogan B, et al. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas. Pol J Radiol 2020; 85: e254-e60. doi: 10.5114/pjr.2020.95945
- Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011; 38: 1191-202. doi: 10.1007/s00259-011-1755-7
- Martínez A, Infante JR, Quirós J, Rayo JI, Serrano J, Moreno M, et al. Baseline 18F-FDG PET/CT quantitative parameters as prognostic factors in esophageal squamous cell cancer. Rev Esp Med Nucl Imagen Mol 2022; 41: 164-70. doi: 10.1016/j.remnie.2021.07.006
Language: English
Page range: 346 - 355
Submitted on: Jun 7, 2026
Accepted on: Jul 26, 2026
Published on: Sep 7, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Milica Kotur, Strahinja Odalovic, Jelena Petrovic, Nikola Pantic, Isidora Grozdic Milojevic, Dragana Sobic Saranovic, Predrag Sabljak, Vera Artiko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.